Diacomit is an FDA-approved anticonvulsant developed specifically for the treatment of seizures associated with Dravet Syndrome in children 6 months and older who weigh at least 7 kg, and who are also being treated with clobazam.
It is designed to help reduce seizure frequency, allowing families to spend less time managing seizures and more time celebrating everyday progress.
Stiripentol works by enhancing the effect of GABA, an inhibitory neurotransmitter in the brain, and also by boosting the effects of other anticonvulsants.